The clinical classification of BC is based on the expression of three clinically validated biomarkers associated with prognosis and treatment options: estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [2]. This evidence concerns the gene ESR1 and breast cancer.